drugset

Drugs / CT-P43

Follow last change Dec 2025 re-read 2 minutes ago

CT-P43

Protein / enzyme biologic

Developed for: psoriasis
Investigated by: Celltrion

Trials 2 · a red edge is where a trial was stopped

today NCT04673786 · Ph 3 NCT04428814 · Ph 1

202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT04428814	Aug 2020 → Feb 2021	—	Celltrion	Completed	No outcome recorded
Phase 31 trial
Phase 3	NCT04673786	Jan → Aug 2021	psoriasis	Celltrion	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06951828 Comparator	May → Nov 2025	—	Celltrion	Completed	No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	CT-P43	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04673786 ↗ 2 NCT06951828 ↗ NCT04428814 ↗
Modality	Protein / enzyme biologic	“CT-P43 is being developed as a proposed biosimilar of Stelara (ustekinumab).” NCT04428814 ↗
Route	Subcutaneous	“CT-P43, 45 mg in 0.5 ml, a single subcutaneous (SC) injection via auto-injector (AI)” NCT06951828 ↗